Literature DB >> 9866001

Sex hormone binding globulin and free levonorgestrel index in the first week after insertion of Norplant implants.

F Alvarez1, V Brache, A S Tejada, L Cochon, A Faundes.   

Abstract

Levonorgestrel has an inhibitory effect on sex hormone binding globulin (SHBG). This decrease in SHBG leads to an increase in the free levonorgestrel index (FLI), which has a stronger biological effect. The interaction between serum levels of levonorgestrel and SHBG in long-term users of Norplant implants has been described. This study was designed to understand the same interaction immediately after the insertion of the implants, in a group of 16 women, sampled at 0 and 6 h and at 1, 3, and 7 days after Norplant implant insertion. Peak serum levonorgestrel levels were achieved at 24 h after insertion, remaining stable on day 3 and decreasing by > 10% by day 7. SHBG did not change during the first 24 h, but decreased by 19% and 60% on days 3 and 7, respectively. FLI more than doubled from day 1 to day 7 after insertion. The large decrease in SHBG and doubling of FLI is not followed by a similar reduction in levonorgestrel, which is hard to explain without an increase in the release rate of the steroid from the capsule.

Entities:  

Keywords:  Americas; Caribbean; Clinical Research; Contraception; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Implants; Contraceptive Methods; Developing Countries; Dominican Republic; Family Planning; Latin America; Levonorgestrel--pharmacodynamics; North America; Research Methodology; Research Report

Mesh:

Substances:

Year:  1998        PMID: 9866001     DOI: 10.1016/s0010-7824(98)00102-4

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  5 in total

1.  Simultaneous quantitation of multiple contraceptive hormones in human serum by LC-MS/MS.

Authors:  Steven W Blue; Andrea J Winchell; Amy V Kaucher; Rachel A Lieberman; Christopher T Gilles; Maria N Pyra; Renee Heffron; Xuanlin Hou; Robert W Coombs; Kavita Nanda; Nicole L Davis; Athena P Kourtis; Joshua T Herbeck; Jared M Baeten; Jairam R Lingappa; David W Erikson
Journal:  Contraception       Date:  2018-01-31       Impact factor: 3.375

2.  Cohort study to evaluate efficacy, safety and acceptability of a two-rod contraceptive implant during third, fourth and fifth year of product use in China.

Authors:  Y Che; D Taylor; D Luo; L Y Maldonado; M Wang; S Wevill; H Vahdat; X Han; V Halpern; L Dorflinger; M J Steiner
Journal:  Contracept X       Date:  2019

3.  Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Authors:  Andrea Ries Thurman; Jill L Schwartz; Vivian Brache; Meredith R Clark; Timothy McCormick; Neelima Chandra; Mark A Marzinke; Frank Z Stanczyk; Charlene S Dezzutti; Sharon L Hillier; Betsy C Herold; Raina Fichorova; Susana N Asin; Christiane Rollenhagen; Debra Weiner; Patrick Kiser; Gustavo F Doncel
Journal:  PLoS One       Date:  2018-06-28       Impact factor: 3.240

4.  Randomized trial to evaluate contraceptive efficacy, safety and acceptability of a two-rod contraceptive implant over 4 years in the Dominican Republic.

Authors:  M J Steiner; V Brache; D Taylor; R Callahan; V Halpern; A Jorge; S Wevill; J Sergison; L Venkatasubramanian; L Dorflinger
Journal:  Contracept X       Date:  2019

5.  Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index.

Authors:  Melissa Natavio; Frank Z Stanczyk; Emilie A G Molins; Anita Nelson; William J Jusko
Journal:  Contraception       Date:  2019-01-28       Impact factor: 3.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.